{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,18]],"date-time":"2026-06-18T05:17:13Z","timestamp":1781759833241,"version":"3.54.5"},"reference-count":56,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2025,11,28]],"date-time":"2025-11-28T00:00:00Z","timestamp":1764288000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2025,11,28]],"date-time":"2025-11-28T00:00:00Z","timestamp":1764288000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"DOI":"10.13039\/501100001665","name":"Agence Nationale de la Recherche","doi-asserted-by":"publisher","award":["ANR-18-IDEX-0001"],"award-info":[{"award-number":["ANR-18-IDEX-0001"]}],"id":[{"id":"10.13039\/501100001665","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Cell Death Dis"],"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:p>\n                    Acyl coenzyme A binding protein (ACBP), also known as diazepam binding inhibitor (DBI), suppresses autophagy, stimulates food intake, and regulates body composition. This tissue hormone contributes to the development of age-related diseases such as metabolic syndrome, cardiovascular disease, cancer, and osteoarthritis. ACBP\/DBI also plays a key pathogenic role in liver disorders, including hepatocellular carcinoma (HCC). Circulating levels of ACBP\/DBI are elevated in patients with histologically diagnosed steatosis, liver fibrosis or HCC, and correlate with disease severity. Moreover, the incidence of liver cancers increases in individuals receiving benzodiazepines, which act on the same binding sites of the GABA-A receptor as ACBP\/DBI. In mice, inhibiting ACBP\/DBI, via inducible knockout, mutation of its receptor (the \u03b32 subunit of the GABA-A receptor) or antibody-mediated neutralization, alleviates various liver conditions, including ischemia-reperfusion injury, bile duct obstruction, hepatotoxicity of acetaminophen, CCl\n                    <jats:sub>4<\/jats:sub>\n                    , ethanol, or concanavalin A, metabolic dysfunction-associated fatty liver disease, and HCC. Importantly, the anti-tumor effects of ACBP\/DBI neutralization are not solely due to its hepatoprotective properties, as they persist in mouse models of HCC driven by oncogenes (e.g., \u03b2-catenin and MYC) or orthotopic injection of syngeneic liver cancer cells into immunocompetent hosts. Notably, hepatocellular carcinoma (HCC) is one of the few cancers in which elevated local ACBP\/DBI expression is associated with poor clinical prognosis. In sum, ACBP\/DBI functions as both a biomarker and a potential therapeutic target for malignant and non-malignant liver diseases.\n                  <\/jats:p>","DOI":"10.1038\/s41419-025-08148-0","type":"journal-article","created":{"date-parts":[[2025,11,28]],"date-time":"2025-11-28T14:49:46Z","timestamp":1764341386000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":3,"title":["ACBP\/DBI neutralization for the prevention and treatment of malignant and non-malignant liver diseases"],"prefix":"10.1038","volume":"16","author":[{"given":"Sijing","family":"Li","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Flavia","family":"Lambertucci","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-4778-4757","authenticated-orcid":false,"given":"L\u00e9a","family":"Mont\u00e9gut","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Isabelle","family":"Martins","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-8355-7562","authenticated-orcid":false,"given":"Jonathan","family":"Pol","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-2919-1296","authenticated-orcid":false,"given":"Mauro","family":"Piacentini","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-9760-7674","authenticated-orcid":false,"given":"Maria Chiara","family":"Maiuri","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-9334-4405","authenticated-orcid":false,"given":"Guido","family":"Kroemer","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2025,11,28]]},"reference":[{"key":"8148_CR1","doi-asserted-by":"publisher","first-page":"325","DOI":"10.1146\/annurev-physiol-022724-105515","volume":"87","author":"M Dukewich","year":"2025","unstructured":"Dukewich M, Yuan L, Terrault NA. At the crossroads of health and disease: consequences of fat in the liver. Annu Rev Physiol. 2025;87:325\u201352.","journal-title":"Annu Rev Physiol"},{"key":"8148_CR2","doi-asserted-by":"publisher","first-page":"439","DOI":"10.1146\/annurev-pathmechdis-031521-024831","volume":"18","author":"T Martini","year":"2023","unstructured":"Martini T, Naef F, Tchorz JS. Spatiotemporal metabolic liver zonation and consequences on pathophysiology. Annu Rev Pathol. 2023;18:439\u201366.","journal-title":"Annu Rev Pathol"},{"key":"8148_CR3","doi-asserted-by":"publisher","first-page":"375","DOI":"10.1146\/annurev-immunol-090122-041354","volume":"42","author":"K Kawashima","year":"2024","unstructured":"Kawashima K, Andreata F, Beccaria CG, Iannacone M. Priming and maintenance of adaptive immunity in the liver. Annu Rev Immunol. 2024;42:375\u201399.","journal-title":"Annu Rev Immunol"},{"key":"8148_CR4","doi-asserted-by":"publisher","first-page":"1852","DOI":"10.1016\/j.cmet.2023.10.009","volume":"35","author":"K Sawada","year":"2023","unstructured":"Sawada K, Chung H, Softic S, Moreno-Fernandez ME, Divanovic S. The bidirectional immune crosstalk in metabolic dysfunction-associated steatotic liver disease. Cell Metab. 2023;35:1852\u201371.","journal-title":"Cell Metab"},{"key":"8148_CR5","doi-asserted-by":"publisher","first-page":"33","DOI":"10.1016\/j.cell.2020.11.034","volume":"184","author":"C Lopez-Otin","year":"2021","unstructured":"Lopez-Otin C, Kroemer G. Hallmarks of health. Cell. 2021;184:33\u201363.","journal-title":"Cell"},{"key":"8148_CR6","doi-asserted-by":"publisher","first-page":"1542","DOI":"10.1016\/j.jhep.2023.06.003","volume":"79","author":"ME Rinella","year":"2023","unstructured":"Rinella ME, Lazarus JV, Ratziu V, Francque SM, Sanyal AJ, Kanwal F, et al. A multisociety Delphi consensus statement on new fatty liver disease nomenclature. J Hepatol. 2023;79:1542\u201356.","journal-title":"J Hepatol"},{"key":"8148_CR7","doi-asserted-by":"publisher","first-page":"662","DOI":"10.1038\/s41575-023-00832-w","volume":"20","author":"S Sharma","year":"2023","unstructured":"Sharma S, Le Guillou D, Chen JY. Cellular stress in the pathogenesis of nonalcoholic steatohepatitis and liver fibrosis. Nat Rev Gastroenterol Hepatol. 2023;20:662\u201378.","journal-title":"Nat Rev Gastroenterol Hepatol"},{"key":"8148_CR8","doi-asserted-by":"publisher","first-page":"275","DOI":"10.1002\/1878-0261.13685","volume":"19","author":"M Karin","year":"2025","unstructured":"Karin M, Kim JY. MASH as an emerging cause of hepatocellular carcinoma: current knowledge and future perspectives. Mol Oncol. 2025;19:275\u201394.","journal-title":"Mol Oncol"},{"key":"8148_CR9","doi-asserted-by":"publisher","first-page":"864","DOI":"10.1038\/s41571-023-00825-3","volume":"20","author":"AG Singal","year":"2023","unstructured":"Singal AG, Kanwal F, Llovet JM. Global trends in hepatocellular carcinoma epidemiology: implications for screening, prevention and therapy. Nat Rev Clin Oncol. 2023;20:864\u201384.","journal-title":"Nat Rev Clin Oncol"},{"key":"8148_CR10","doi-asserted-by":"publisher","first-page":"1564","DOI":"10.1056\/NEJMra2022774","volume":"383","author":"N Mizushima","year":"2020","unstructured":"Mizushima N, Levine B. Autophagy in human diseases. N Engl J Med. 2020;383:1564\u201376.","journal-title":"N Engl J Med"},{"key":"8148_CR11","doi-asserted-by":"publisher","first-page":"243","DOI":"10.1038\/s41556-018-0042-2","volume":"20","author":"MD Rybstein","year":"2018","unstructured":"Rybstein MD, Bravo-San Pedro JM, Kroemer G, Galluzzi L. The autophagic network and cancer. Nat Cell Biol. 2018;20:243\u201351.","journal-title":"Nat Cell Biol"},{"key":"8148_CR12","doi-asserted-by":"publisher","first-page":"33","DOI":"10.1007\/s10555-025-10250-w","volume":"44","author":"X Yang","year":"2025","unstructured":"Yang X, Cao X, Zhu Q. p62\/SQSTM1 in cancer: phenomena, mechanisms, and regulation in DNA damage repair. Cancer Metastasis Rev. 2025;44:33.","journal-title":"Cancer Metastasis Rev"},{"key":"8148_CR13","doi-asserted-by":"publisher","first-page":"795","DOI":"10.1101\/gad.2016211","volume":"25","author":"A Takamura","year":"2011","unstructured":"Takamura A, Komatsu M, Hara T, Sakamoto A, Kishi C, Waguri S, et al. Autophagy-deficient mice develop multiple liver tumors. Genes Dev. 2011;25:795\u2013800.","journal-title":"Genes Dev"},{"key":"8148_CR14","doi-asserted-by":"publisher","first-page":"890","DOI":"10.1016\/j.tem.2021.08.009","volume":"32","author":"T Alquier","year":"2021","unstructured":"Alquier T, Christian-Hinman CA, Alfonso J. Faergeman NJ. From benzodiazepines to fatty acids and beyond: revisiting the role of ACBP\/DBI. Trends Endocrinol Metab. 2021;32:890\u2013903.","journal-title":"Trends Endocrinol Metab"},{"key":"8148_CR15","doi-asserted-by":"publisher","first-page":"134","DOI":"10.1038\/s41419-025-07447-w","volume":"16","author":"S Li","year":"2025","unstructured":"Li S, Mingoia S, Mont\u00e9gut L, Lambertucci F, Chen H, Dong Y, et al. Atlas of expression of acyl CoA binding protein\/diazepam binding inhibitor (ACBP\/DBI) in human and mouse. Cell Death Dis. 2025;16:134.","journal-title":"Cell Death Dis"},{"key":"8148_CR16","doi-asserted-by":"publisher","DOI":"10.1111\/acel.13910","volume":"22","author":"L Montegut","year":"2023","unstructured":"Montegut L, Abdellatif M, Motino O, Madeo F, Martins I, Quesada V, et al. Acyl coenzyme A binding protein (ACBP): an aging- and disease-relevant \u201cautophagy checkpoint. Aging Cell. 2023;22:e13910.","journal-title":"Aging Cell"},{"key":"8148_CR17","doi-asserted-by":"publisher","DOI":"10.1016\/j.pharmthera.2019.06.008","volume":"208","author":"MC Tonon","year":"2020","unstructured":"Tonon MC, Vaudry H, Chuquet J, Guillebaud F, Fan J, Masmoudi-Kouki O, et al. Endozepines and their receptors: structure, functions and pathophysiological significance. Pharmacol Ther. 2020;208:107386.","journal-title":"Pharmacol Ther"},{"key":"8148_CR18","doi-asserted-by":"publisher","first-page":"253","DOI":"10.1111\/jnc.13035","volume":"133","author":"K Bouyakdan","year":"2015","unstructured":"Bouyakdan K, Taib B, Budry L, Zhao S, Rodaros D, Neess D, et al. A novel role for central ACBP\/DBI as a regulator of long-chain fatty acid metabolism in astrocytes. J Neurochem. 2015;133:253\u201365.","journal-title":"J Neurochem"},{"key":"8148_CR19","doi-asserted-by":"publisher","first-page":"274","DOI":"10.1016\/j.cmet.2019.04.004","volume":"30","author":"C Duman","year":"2019","unstructured":"Duman C, Yaqubi K, Hoffmann A, Acikgoz AA, Korshunov A, Bendszus M, et al. Acyl-CoA-binding protein drives glioblastoma tumorigenesis by sustaining fatty acid oxidation. Cell Metab. 2019;30:274\u201389.e275.","journal-title":"Cell Metab"},{"key":"8148_CR20","doi-asserted-by":"publisher","DOI":"10.1126\/scitranslmed.ado7225","volume":"17","author":"H Teng","year":"2025","unstructured":"Teng H, Hang Q, Zheng C, Yan Y, Liu S, Zhao Y, et al. In vivo CRISPR activation screen identifies acyl-CoA-binding protein as a driver of bone metastasis. Sci Transl Med. 2025;17:eado7225.","journal-title":"Sci Transl Med"},{"key":"8148_CR21","doi-asserted-by":"crossref","unstructured":"Blasco-Roset A, Quesada-Lopez T, Mestres-Arenas A, Villarroya J, Godoy-Nieto FJ, Cereijo R, et al. Acyl CoA-binding protein in brown adipose tissue acts as a negative regulator of adaptive thermogenesis. Mol Metab. 2025;96:102153.","DOI":"10.1016\/j.molmet.2025.102153"},{"key":"8148_CR22","doi-asserted-by":"crossref","unstructured":"Wu T, Huang T, Ren H, Shen C, Qian J, Fu X, et al. Metabolic coordination structures contribute to diabetic myocardial dysfunction. Circ Res. 2025;136:946\u201367.","DOI":"10.1161\/CIRCRESAHA.124.326044"},{"key":"8148_CR23","doi-asserted-by":"publisher","DOI":"10.1073\/pnas.2207344119","volume":"119","author":"O Motino","year":"2022","unstructured":"Motino O, Lambertucci F, Anagnostopoulos G, Li S, Nah J, Castoldi F, et al. ACBP\/DBI protein neutralization confers autophagy-dependent organ protection through inhibition of cell loss, inflammation, and fibrosis. Proc Natl Acad Sci USA. 2022;119:e2207344119.","journal-title":"Proc Natl Acad Sci USA"},{"key":"8148_CR24","doi-asserted-by":"publisher","first-page":"754","DOI":"10.1016\/j.cmet.2019.07.010","volume":"30","author":"JM Bravo-San Pedro","year":"2019","unstructured":"Bravo-San Pedro JM, Sica V, Martins I, Pol J, Loos F, Maiuri MC, et al. Acyl-CoA-Binding Protein is a lipogenic factor that triggers food intake and obesity. Cell Metab. 2019;30:754\u201367.e759.","journal-title":"Cell Metab"},{"key":"8148_CR25","doi-asserted-by":"publisher","first-page":"102232","DOI":"10.1016\/j.xcrm.2025.102232","volume":"6","author":"S Li","year":"2025","unstructured":"Li S, Moti\u00f1o O, Lambertucci F, Pol J, Chen H, Pan L, et al. Neutralization of acyl coenzyme A binding protein for the experimental prevention and treatment of hepatocellular carcinoma. Cell Rep Med. 2025;6:102232.","journal-title":"Cell Rep Med"},{"key":"8148_CR26","doi-asserted-by":"publisher","DOI":"10.1186\/s12943-024-02098-5","volume":"23","author":"L Montegut","year":"2024","unstructured":"Montegut L, Liu P, Zhao L, Perez-Lanzon M, Chen H, Mao M, et al. Acyl-coenzyme a binding protein (ACBP)\u2014a risk factor for cancer diagnosis and an inhibitor of immunosurveillance. Mol Cancer. 2024;23:187.","journal-title":"Mol Cancer"},{"key":"8148_CR27","doi-asserted-by":"publisher","first-page":"434","DOI":"10.1038\/s41418-024-01410-6","volume":"32","author":"O Motino","year":"2025","unstructured":"Motino O, Lambertucci F, Joseph A, Durand S, Anagnostopoulos G, Li S, et al. ACBP\/DBI neutralization for the experimental treatment of fatty liver disease. Cell Death Differ. 2025;32:434\u201346.","journal-title":"Cell Death Differ"},{"key":"8148_CR28","doi-asserted-by":"publisher","first-page":"1484","DOI":"10.1038\/s41418-025-01474-y","volume":"32","author":"U Nogueira-Recalde","year":"2025","unstructured":"Nogueira-Recalde U, Lambertucci F, Montegut L, Motino O, Chen H, Lachkar S, et al. Neutralization of acyl CoA binding protein (ACBP) for the experimental treatment of osteoarthritis. Cell Death Differ. 2025;32:1484\u201398.","journal-title":"Cell Death Differ"},{"key":"8148_CR29","doi-asserted-by":"publisher","DOI":"10.1111\/acel.13751","volume":"22","author":"L Montegut","year":"2023","unstructured":"Montegut L, Joseph A, Chen H, Abdellatif M, Ruckenstuhl C, Motino O, et al. High plasma concentrations of acyl-coenzyme A binding protein (ACBP) predispose to cardiovascular disease: evidence for a phylogenetically conserved proaging function of ACBP. Aging Cell. 2023;22:e13751.","journal-title":"Aging Cell"},{"key":"8148_CR30","doi-asserted-by":"publisher","first-page":"2043","DOI":"10.1016\/j.cell.2025.03.011","volume":"188","author":"G Kroemer","year":"2025","unstructured":"Kroemer G, Maier AB, Cuervo AM, Gladyshev VN, Ferrucci L, Gorbunova V, et al. From geroscience to precision geromedicine: understanding and managing aging. Cell. 2025;188:2043\u201362.","journal-title":"Cell"},{"key":"8148_CR31","doi-asserted-by":"publisher","first-page":"348","DOI":"10.1038\/s41586-023-06563-x","volume":"622","author":"GH Eldjarn","year":"2023","unstructured":"Eldjarn GH, Ferkingstad E, Lund SH, Helgason H, Magnusson OT, Gunnarsdottir K, et al. Large-scale plasma proteomics comparisons through genetics and disease associations. Nature. 2023;622:348\u201358.","journal-title":"Nature"},{"key":"8148_CR32","doi-asserted-by":"publisher","first-page":"1712","DOI":"10.1038\/s41588-021-00978-w","volume":"53","author":"E Ferkingstad","year":"2021","unstructured":"Ferkingstad E, Sulem P, Atlason BA, Sveinbjornsson G, Magnusson MI, Styrmisdottir EL, et al. Large-scale integration of the plasma proteome with genetics and disease. Nat Genet. 2021;53:1712\u201321.","journal-title":"Nat Genet"},{"key":"8148_CR33","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2024.1505752","volume":"15","author":"S Isnard","year":"2024","unstructured":"Isnard S, Mabanga T, Royston L, Berini CA, Bu S, Aiyana O, et al. Extracellular acyl-CoA-binding protein as an independent biomarker of COVID-19 disease severity. Front Immunol. 2024;15:1505752.","journal-title":"Front Immunol"},{"key":"8148_CR34","doi-asserted-by":"publisher","DOI":"10.1038\/s41419-020-2716-5","volume":"11","author":"A Joseph","year":"2020","unstructured":"Joseph A, Moriceau S, Sica V, Anagnostopoulos G, Pol J, Martins I, et al. Metabolic and psychiatric effects of acyl coenzyme A binding protein (ACBP)\/diazepam binding inhibitor (DBI). Cell Death Dis. 2020;11:502.","journal-title":"Cell Death Dis"},{"key":"8148_CR35","doi-asserted-by":"publisher","DOI":"10.1038\/s41419-021-03864-9","volume":"12","author":"A Joseph","year":"2021","unstructured":"Joseph A, Chen H, Anagnostopoulos G, Montegut L, Lafarge A, Motino O, et al. Effects of acyl-coenzyme A binding protein (ACBP)\/diazepam-binding inhibitor (DBI) on body mass index. Cell Death Dis. 2021;12:599.","journal-title":"Cell Death Dis"},{"key":"8148_CR36","doi-asserted-by":"publisher","first-page":"846","DOI":"10.1002\/hep.21496","volume":"45","author":"P Angulo","year":"2007","unstructured":"Angulo P, Hui JM, Marchesini G, Bugianesi E, George J, Farrell GC, et al. The NAFLD fibrosis score: a noninvasive system that identifies liver fibrosis in patients with NAFLD. Hepatology. 2007;45:846\u201354.","journal-title":"Hepatology"},{"key":"8148_CR37","doi-asserted-by":"publisher","first-page":"1317","DOI":"10.1002\/hep.21178","volume":"43","author":"RK Sterling","year":"2006","unstructured":"Sterling RK, Lissen E, Clumeck N, Sola R, Correa MC, Montaner J, et al. Development of a simple noninvasive index to predict significant fibrosis in patients with HIV\/HCV coinfection. Hepatology. 2006;43:1317\u201325.","journal-title":"Hepatology"},{"key":"8148_CR38","doi-asserted-by":"publisher","first-page":"1652","DOI":"10.1038\/s41588-022-01199-5","volume":"54","author":"G Sveinbjornsson","year":"2022","unstructured":"Sveinbjornsson G, Ulfarsson MO, Thorolfsdottir RB, Jonsson BA, Einarsson E, Gunnlaugsson G, et al. Multiomics study of nonalcoholic fatty liver disease. Nat Genet. 2022;54:1652\u201363.","journal-title":"Nat Genet"},{"key":"8148_CR39","doi-asserted-by":"publisher","DOI":"10.1016\/j.xcrm.2025.102085","volume":"6","author":"W De Nardo","year":"2025","unstructured":"De Nardo W, Lee O, Johari Y, Bayliss J, Pensa M, Miotto PM, et al. Integrated liver-secreted and plasma proteomics identify a predictive model that stratifies MASH. Cell Rep Med. 2025;6:102085.","journal-title":"Cell Rep Med"},{"key":"8148_CR40","doi-asserted-by":"publisher","first-page":"e555","DOI":"10.4088\/JCP.11m07333","volume":"73","author":"CH Kao","year":"2012","unstructured":"Kao CH, Sun LM, Su KP, Chang SN, Sung FC, Muo CH, et al. Benzodiazepine use possibly increases cancer risk: a population-based retrospective cohort study in Taiwan. J Clin Psychiatry. 2012;73:e555\u201360.","journal-title":"J Clin Psychiatry"},{"key":"8148_CR41","doi-asserted-by":"publisher","first-page":"1356","DOI":"10.1111\/bcp.12001","volume":"75","author":"A Pottegard","year":"2013","unstructured":"Pottegard A, Friis S, Andersen M, Hallas J. Use of benzodiazepines or benzodiazepine related drugs and the risk of cancer: a population-based case-control study. Br J Clin Pharm. 2013;75:1356\u201364.","journal-title":"Br J Clin Pharm"},{"key":"8148_CR42","doi-asserted-by":"publisher","first-page":"2517","DOI":"10.1111\/bcp.13342","volume":"83","author":"LC Thygesen","year":"2017","unstructured":"Thygesen LC, Pottegard A, Ersboll AK, Friis S, Sturmer T, Hallas J. External adjustment of unmeasured confounders in a case-control study of benzodiazepine use and cancer risk. Br J Clin Pharm. 2017;83:2517\u201327.","journal-title":"Br J Clin Pharm"},{"key":"8148_CR43","doi-asserted-by":"publisher","first-page":"513","DOI":"10.1002\/ijc.30443","volume":"140","author":"HB Kim","year":"2017","unstructured":"Kim HB, Myung SK, Park YC, Park B. Use of benzodiazepine and risk of cancer: a meta-analysis of observational studies. Int J Cancer. 2017;140:513\u201325.","journal-title":"Int J Cancer"},{"key":"8148_CR44","doi-asserted-by":"publisher","first-page":"493","DOI":"10.1038\/nmeth.1928","volume":"9","author":"G Boncompain","year":"2012","unstructured":"Boncompain G, Divoux S, Gareil N, de Forges H, Lescure A, Latreche L, et al. Synchronization of secretory protein traffic in populations of cells. Nat Methods. 2012;9:493\u20138.","journal-title":"Nat Methods"},{"key":"8148_CR45","doi-asserted-by":"publisher","DOI":"10.1126\/scitranslmed.adl0715","volume":"16","author":"H Chen","year":"2024","unstructured":"Chen H, Moriceau S, Joseph A, Mailliet F, Li S, Tolle V, et al. Acyl-CoA binding protein for the experimental treatment of anorexia. Sci Transl Med. 2024;16:eadl0715.","journal-title":"Sci Transl Med"},{"key":"8148_CR46","doi-asserted-by":"publisher","DOI":"10.1038\/s41419-022-04834-5","volume":"13","author":"G Anagnostopoulos","year":"2022","unstructured":"Anagnostopoulos G, Motino O, Li S, Carbonnier V, Chen H, Sica V, et al. An obesogenic feedforward loop involving PPARgamma, acyl-CoA binding protein and GABA(A) receptor. Cell Death Dis. 2022;13:356.","journal-title":"Cell Death Dis"},{"key":"8148_CR47","doi-asserted-by":"publisher","first-page":"567","DOI":"10.1007\/s11745-010-3437-9","volume":"45","author":"D Landrock","year":"2010","unstructured":"Landrock D, Atshaves BP, McIntosh AL, Landrock KK, Schroeder F, Kier AB. Acyl-CoA binding protein gene ablation induces pre-implantation embryonic lethality in mice. Lipids. 2010;45:567\u201380.","journal-title":"Lipids"},{"key":"8148_CR48","doi-asserted-by":"publisher","first-page":"1403","DOI":"10.1016\/j.celrep.2013.11.010","volume":"5","author":"D Neess","year":"2013","unstructured":"Neess D, Bek S, Bloksgaard M, Marcher AB, Faergeman NJ, Mandrup S. Delayed hepatic adaptation to weaning in ACBP-\/- mice is caused by disruption of the epidermal barrier. Cell Rep. 2013;5:1403\u201312.","journal-title":"Cell Rep"},{"key":"8148_CR49","doi-asserted-by":"publisher","first-page":"2281","DOI":"10.1038\/s42255-024-01170-0","volume":"6","author":"H Pan","year":"2024","unstructured":"Pan H, Tian AL, Chen H, Xia Y, Sauvat A, Moriceau S, et al. Pathogenic role of acyl coenzyme A binding protein (ACBP) in Cushing\u2019s syndrome. Nat Metab. 2024;6:2281\u201399.","journal-title":"Nat Metab"},{"key":"8148_CR50","doi-asserted-by":"publisher","DOI":"10.1016\/j.xpro.2021.101095","volume":"3","author":"L Montegut","year":"2022","unstructured":"Montegut L, Chen H, Bravo-San Pedro JM, Motino O, Martins I, Kroemer G. Immunization of mice with the self-peptide ACBP coupled to keyhole limpet hemocyanin. STAR Protoc. 2022;3:101095.","journal-title":"STAR Protoc"},{"key":"8148_CR51","doi-asserted-by":"publisher","DOI":"10.1038\/s41419-024-06633-6","volume":"15","author":"G Anagnostopoulos","year":"2024","unstructured":"Anagnostopoulos G, Saavedra E, Lambertucci F, Motino O, Dimitrov J, Roiz-Valle D, et al. Inhibition of acyl-CoA binding protein (ACBP) by means of a GABA(A)Rgamma2-derived peptide. Cell Death Dis. 2024;15:249.","journal-title":"Cell Death Dis"},{"key":"8148_CR52","doi-asserted-by":"publisher","first-page":"678","DOI":"10.1080\/15548627.2024.2437649","volume":"21","author":"H Pan","year":"2025","unstructured":"Pan H, Tian AL, Castinetti F, Martins I, Kepp O, Kroemer G. Autophagy-dependent hepatocyte secretion of DBI\/ACBP induced by glucocorticoids determines the pathogenesis of Cushing syndrome. Autophagy. 2025;21:678\u201380.","journal-title":"Autophagy"},{"key":"8148_CR53","doi-asserted-by":"publisher","first-page":"48","DOI":"10.1016\/j.cmet.2015.12.015","volume":"23","author":"J Font-Burgada","year":"2016","unstructured":"Font-Burgada J, Sun B, Karin M. Obesity and cancer: the oil that feeds the flame. Cell Metab. 2016;23:48\u201362.","journal-title":"Cell Metab"},{"key":"8148_CR54","doi-asserted-by":"crossref","unstructured":"Lee KW, Kim M, Lee SH, Kim KD. The function of autophagy as a regulator of melanin homeostasis. Cells 2022;11:2085.","DOI":"10.3390\/cells11132085"},{"key":"8148_CR55","doi-asserted-by":"publisher","DOI":"10.1038\/s41467-020-17644-0","volume":"11","author":"A Buque","year":"2020","unstructured":"Buque A, Bloy N, Perez-Lanzon M, Iribarren K, Humeau J, Pol JG, et al. Immunoprophylactic and immunotherapeutic control of hormone receptor-positive breast cancer. Nat Commun. 2020;11:3819.","journal-title":"Nat Commun"},{"key":"8148_CR56","doi-asserted-by":"publisher","DOI":"10.1080\/2162402X.2024.2413719","volume":"13","author":"L Montegut","year":"2024","unstructured":"Montegut L, Derosa L, Messaoudene M, Chen H, Lambertucci F, Routy B, et al. Benzodiazepines compromise the outcome of cancer immunotherapy. Oncoimmunology. 2024;13:2413719.","journal-title":"Oncoimmunology"}],"container-title":["Cell Death &amp; Disease"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/s41419-025-08148-0.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41419-025-08148-0","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41419-025-08148-0.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,11,28]],"date-time":"2025-11-28T16:02:50Z","timestamp":1764345770000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s41419-025-08148-0"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,11,28]]},"references-count":56,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2025,12]]}},"alternative-id":["8148"],"URL":"https:\/\/doi.org\/10.1038\/s41419-025-08148-0","relation":{},"ISSN":["2041-4889"],"issn-type":[{"value":"2041-4889","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,11,28]]},"assertion":[{"value":"8 July 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"10 September 2025","order":2,"name":"revised","label":"Revised","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"13 October 2025","order":3,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"28 November 2025","order":4,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"IM is a consultant of Osasuna Therapeutics. GK has been holding research contracts with Daiichi Sankyo, Eleor, Kaleido, Lytix Pharma, PharmaMar, Osasuna Therapeutics, Samsara Therapeutics, Sanofi, Sutro, Tollys, and Vascage. GK is on the Board of Directors of the Bristol Myers Squibb Foundation France. GK is a scientific co-founder of everImmune, Osasuna Therapeutics, Samsara Therapeutics and Therafast Bio. GK is in the scientific advisory boards of Hevolution, Institut Servier, and Rejuveron Life Sciences\/Centenara Labs AG. GK is the inventor of patents covering therapeutic targeting of aging, cancer, cystic fibrosis and metabolic disorders. Among these patents, one \u201cMethods for weight reduction\u201d (US11905330B1) is relevant to this study. GK\u2019s brother, Romano Kroemer, was an employee of Sanofi and now consults for Boehringer-Ingelheim. GK\u2019s wife, Laurence Zitvogel, has held research contracts with Glaxo Smyth Kline, Incyte, Lytix, Kaleido, Innovate Pharma, Daiichi Sankyo, Pilege, Merus, Transgene, 9\u2009m, Tusk and Roche, was on the on the Board of Directors of Transgene, is a co-founder of everImmune, and holds patents covering the treatment of cancer and the therapeutic manipulation of the microbiota. MCM is the inventor of a patent covering therapeutic targeting of cancer, not relevant with this study. The funders had no role in the design of the study; in the writing of the manuscript, or in the decision to publish the results.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}},{"value":"Mice were bred and maintained according to the Federation of European Laboratory Animal Science Associations (FELASA) guidelines, and approved by the local Animal Experimental Ethics Committee (project number #25000-2020040718432518v4). Animals were allowed to acclimate for one week, provided with food ad libitum, and housed collectively in a temperature-controlled environment with 12-h light-dark cycles. The size of mice groups (\n                      n\n                      \u2009=\u200920) was estimated based on previous investigations [\n                      \n                      ]. Randomization was performed using the software RandoMice.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval"}}],"article-number":"863"}}